JP5298334B2 - 性機能障害を治療する方法 - Google Patents
性機能障害を治療する方法 Download PDFInfo
- Publication number
- JP5298334B2 JP5298334B2 JP2008518221A JP2008518221A JP5298334B2 JP 5298334 B2 JP5298334 B2 JP 5298334B2 JP 2008518221 A JP2008518221 A JP 2008518221A JP 2008518221 A JP2008518221 A JP 2008518221A JP 5298334 B2 JP5298334 B2 JP 5298334B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- sexual dysfunction
- therapeutic agent
- group
- optical isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000001880 Sexual dysfunction Diseases 0.000 title claims abstract description 76
- 231100000872 sexual dysfunction Toxicity 0.000 title claims abstract description 76
- 150000001875 compounds Chemical class 0.000 claims abstract description 135
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims description 95
- 230000003287 optical effect Effects 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 61
- 238000012360 testing method Methods 0.000 claims description 43
- 229940124597 therapeutic agent Drugs 0.000 claims description 34
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 17
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 16
- 239000005557 antagonist Substances 0.000 claims description 12
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 9
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 9
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 9
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 9
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 8
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 8
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 7
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 7
- 230000002441 reversible effect Effects 0.000 claims description 7
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 7
- 229960004688 venlafaxine Drugs 0.000 claims description 7
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 6
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 6
- 229960002464 fluoxetine Drugs 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 5
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 5
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 5
- 229960000600 milnacipran Drugs 0.000 claims description 5
- 229960002296 paroxetine Drugs 0.000 claims description 5
- 150000003335 secondary amines Chemical class 0.000 claims description 5
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 5
- 150000003512 tertiary amines Chemical class 0.000 claims description 5
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 4
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 4
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 4
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 4
- MPZVHKLZCUEJFO-UHFFFAOYSA-N N-[3-(2-acetamidoethyl)-1H-indol-5-yl]carbamic acid methyl ester Chemical compound COC(=O)NC1=CC=C2NC=C(CCNC(C)=O)C2=C1 MPZVHKLZCUEJFO-UHFFFAOYSA-N 0.000 claims description 4
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 4
- UCTRAOBQFUDCSR-SECBINFHSA-N [(2r)-2-amino-3-phenylpropyl] carbamate Chemical compound NC(=O)OC[C@H](N)CC1=CC=CC=C1 UCTRAOBQFUDCSR-SECBINFHSA-N 0.000 claims description 4
- 229960000836 amitriptyline Drugs 0.000 claims description 4
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 4
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims description 4
- 229960002519 amoxapine Drugs 0.000 claims description 4
- XNRHTMDHGDWBGP-UHFFFAOYSA-N carbamic acid;hydrochloride Chemical compound Cl.NC(O)=O XNRHTMDHGDWBGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229960001653 citalopram Drugs 0.000 claims description 4
- 229960004606 clomipramine Drugs 0.000 claims description 4
- 229960003914 desipramine Drugs 0.000 claims description 4
- 229960005426 doxepin Drugs 0.000 claims description 4
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 4
- 229960002866 duloxetine Drugs 0.000 claims description 4
- 229960004038 fluvoxamine Drugs 0.000 claims description 4
- 229960004801 imipramine Drugs 0.000 claims description 4
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 4
- 229960004090 maprotiline Drugs 0.000 claims description 4
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 4
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004644 moclobemide Drugs 0.000 claims description 4
- 229960001158 nortriptyline Drugs 0.000 claims description 4
- 229960002601 protriptyline Drugs 0.000 claims description 4
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 4
- 229960002073 sertraline Drugs 0.000 claims description 4
- 239000002462 tachykinin receptor antagonist Substances 0.000 claims description 4
- 229960002431 trimipramine Drugs 0.000 claims description 4
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 4
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 claims description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 3
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 3
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims description 3
- 229960002672 isocarboxazid Drugs 0.000 claims description 3
- 239000002618 kappa opiate receptor antagonist Substances 0.000 claims description 3
- 229960000964 phenelzine Drugs 0.000 claims description 3
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000002160 alpha blocker Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 44
- -1 nitro, hydroxy Chemical group 0.000 abstract description 29
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 28
- 150000002148 esters Chemical class 0.000 abstract description 26
- 125000000217 alkyl group Chemical group 0.000 abstract description 16
- 125000003118 aryl group Chemical group 0.000 abstract description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract description 10
- 125000004430 oxygen atom Chemical group O* 0.000 abstract description 10
- 125000003545 alkoxy group Chemical group 0.000 abstract description 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract description 5
- 229910052794 bromium Inorganic materials 0.000 abstract description 5
- 150000001923 cyclic compounds Chemical class 0.000 abstract description 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 5
- 229910052740 iodine Inorganic materials 0.000 abstract description 5
- 125000005309 thioalkoxy group Chemical group 0.000 abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 49
- 235000002639 sodium chloride Nutrition 0.000 description 42
- 230000000694 effects Effects 0.000 description 38
- 238000011282 treatment Methods 0.000 description 36
- 230000001568 sexual effect Effects 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 239000000935 antidepressant agent Substances 0.000 description 22
- 229940005513 antidepressants Drugs 0.000 description 21
- 239000002552 dosage form Substances 0.000 description 21
- 238000009472 formulation Methods 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- 230000004044 response Effects 0.000 description 20
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 19
- 230000001430 anti-depressive effect Effects 0.000 description 17
- 206010057671 Female sexual dysfunction Diseases 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- 230000036332 sexual response Effects 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 230000037007 arousal Effects 0.000 description 10
- 239000000969 carrier Substances 0.000 description 10
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 230000000306 recurrent effect Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000002085 persistent effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 208000021663 Female sexual arousal disease Diseases 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 229960001058 bupropion Drugs 0.000 description 7
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 208000012201 sexual and gender identity disease Diseases 0.000 description 7
- 208000015891 sexual disease Diseases 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 210000004392 genitalia Anatomy 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- 230000006399 behavior Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000009429 distress Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229940008015 lithium carbonate Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 206010057672 Male sexual dysfunction Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000027520 Somatoform disease Diseases 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229940030600 antihypertensive agent Drugs 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 229960003399 estrone Drugs 0.000 description 4
- 208000014840 female orgasmic disease Diseases 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 201000004197 inhibited female orgasm Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 208000027753 pain disease Diseases 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000008238 Muscle Spasticity Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102000003141 Tachykinin Human genes 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000000768 catecholaminergic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007859 condensation product Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 239000012458 free base Chemical group 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 3
- 229960003946 selegiline Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 3
- 230000009329 sexual behaviour Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 208000018198 spasticity Diseases 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108060008037 tachykinin Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229960003741 tranylcypromine Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 206010061979 Genital pain Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 2
- 208000030047 Sexual desire disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 2
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000035946 sexual desire Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000012439 solid excipient Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 206010046947 vaginismus Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 0 *CC(Cc1ccccc1)N Chemical compound *CC(Cc1ccccc1)N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002652 Anorgasmia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003439 Artificial menopause Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010067639 Genital swelling Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000030431 Male orgasmic disease Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010058674 Pelvic Infection Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000029899 Sexual aversion disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- BQYRVMAWJCIIKI-UHFFFAOYSA-N carbamic acid;1-phenylethane-1,2-diol Chemical compound NC(O)=O.OCC(O)C1=CC=CC=C1 BQYRVMAWJCIIKI-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- ZEUITGRIYCTCEM-UHFFFAOYSA-N duloxetine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCNC)C1=CC=CS1 ZEUITGRIYCTCEM-UHFFFAOYSA-N 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229940063155 estrone 0.25 mg Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 201000000068 inhibited male orgasm Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229940015418 ketaset Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000001045 lordotic effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 208000015421 male orgasm disease Diseases 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- GJJFMKBJSRMPLA-UHFFFAOYSA-N milnacipran Chemical compound C=1C=CC=CC=1C1(C(=O)N(CC)CC)CC1CN GJJFMKBJSRMPLA-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000024309 orgasm disease Diseases 0.000 description 1
- 229940054010 other antipsychotics in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- BLFQGGGGFNSJKA-XHXSRVRCSA-N sertraline hydrochloride Chemical compound Cl.C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-XHXSRVRCSA-N 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Description
がこれらの様相、通常は欲求、興奮又はオルガスムに於けるいずれかの1つ以 上の欠如、不十分な又は不満足な応答を持つ場合に起こる。
DSM−IVは、上記4つのクラスを以下の通りに定義する。
性交疼痛症は、性交に関連する再発性又は持続性の性器痛である。膣痙は、性交を妨げる持続性又は再発性の膣外端3分の1の筋肉組織の無意識の痙攣である。
1)HSDDは、個人の苦痛を引き起こす、持続性又は再発性の、性的空想/想像、及び/又は欲望又は性活動の受容力の欠乏(又は欠如)である。
HSDDは、女性が全く又はほとんど性的である欲望を持たない場合及び、全く又はほとんど性的想像又は空想を持たない場合、存在する。FSDのこのタイプは、低テストステロン量に起因し得、自然閉経か又は外科的閉経が原因である。閉経前の女性(即ち、閉経前及び子宮摘出を受けていない女性)並びに閉経後の女性の両方に於けるその他の原因としては、例えば、疾患、投薬、倦怠感、うつ病、及び/又は不安が挙げられる。関係障害又は宗教的な要因などの精神的影響の可能性(意識的又は潜在意識的)を持つ要因は、女性に於けるHSDDの存在/発生と関係し得る。
薬、降圧剤及びその他多くの種類の一般的に用いられる医薬によって引き起こされ得、又は悪化し得る。全ての年齢及び両性に於けるこれらの医薬の大量使用を考慮して、医薬誘発性機能障害を治療する方法を開発する事は特に重要である。
本発明は、被験者の性機能障害を治療する方法であって、式(1):
Rxは、水素原子、炭素原子数1ないし8の低級アルキル基、F、Cl、Br及びIより選ばれたハロゲン原子、1ないし3個の炭素原子を有するアルコキシ基、ニトロ基、ヒドロキシ基、トリフルオロメチル基、及び1ないし3個の炭素原子を有するチオアルコキシ基からなる群から選択された一つを表し;
xは、1ないし3の整数を表し、ただし、xが2又は3のとき、Rは同じでも異なっていても良い;
R1及びR2は互いに同じでも異なっていてもよく、それぞれ独立して、水素原子、炭素原子数1ないし8の低級アルキル基、アリール基、アリールアルキル基、炭素原子数3ないし7のシクロアルキル基からなる群より選ばれ;
R1及びR2は、一緒になって、水素原子、アルキル基及びアリール基からなる群から選択された一つで置換された5ないし7員の複素環を形成し得;
ここで、環状化合物は1ないし2個の窒素原子及び0ないし1個の酸素原子を含み得;
ここで、前記窒素原子は互いに又は前記酸素原子と直接結合しない。)
で表される化合物又はその医薬品として許容できる塩又はエステルの治療有効量を、前記治療を必要とする被験者に投与する工程を含む方法に関する。
実質的に他の光学異性体を含まない式1:
Rxは、水素原子、炭素原子数1ないし8の低級アルキル基、F、Cl、Br及びIより選ばれるハロゲン原子、1ないし3個の炭素原子を有するアルコキシ基、ニトロ基、ヒドロキシ基、トリフルオロメチル基、及び1ないし3個の炭素原子を有するチオアルコキシ基からなる群から選択された一つを表し;
xは、1ないし3の整数を表し、ただし、xが2又は3のとき、Rは同じでも異なっていても良い;
R1及びR2は互いに同じでも異なっていてもよく、それぞれ独立して、水素原子、炭素原子数1ないし8の低級アルキル基、アリール基、アリールアルキル基、炭素原子数3ないし7のシクロアルキル基からなる群より選ばれ;
R1及びR2は、一緒になって、水素原子、アルキル基及びアリール基からなる群から選択された一つで置換された5ないし7員の複素環を形成し得;
ここで、環状化合物は1ないし2個の窒素原子及び0ないし1個の酸素原子を含も得;
ここで、前記窒素原子は互いに又は前記酸素原子と直接結合しない。)
の光学異性体又は式1の光学異性体の一つが優勢である光学異性体の混合物又はその医薬品として許容できる塩又はエステルの治療有効量を、前記治療を必要とする被験者に投与する工程を含む、被験者の性機能障害を治療する方法を含む。
Rxは、水素原子、炭素原子数1ないし8の低級アルキル基、F、Cl、Br及びIよ
り選ばれたハロゲン原子、1ないし3個の炭素原子を有するアルコキシ基、ニトロ基、ヒドロキシ基、トリフルオロメチル基、及び1ないし3個の炭素原子を有するチオアルコキシ基からなる群から選択された一つを表し;
xは、1ないし3の整数を表し、ただし、xが2又は3のとき、Rは同じでも異なっていても良い;
R1及びR2は互いに同じでも異なっていてもよく、それぞれ独立して、水素原子、炭素原子数1ないし8の低級アルキル基、アリール基、アリールアルキル基、炭素原子数3ないし7のシクロアルキル基からなる群より選ばれ;
R1及びR2は、一緒になって、水素原子、アルキル基及びアリール基からなる群から選択された一つで置換された5ないし7員の複素環を形成し得;
ここで、環状化合物は1ないし2個の窒素原子及び0ないし1個の酸素原子を含み得;
ここで、前記窒素原子は互いに又は前記酸素原子と直接結合しない。
図1は、雌ラットの前湾反応に於ける様々な用量の試験化合物の効果を、媒体及び活性対照のキネロランと比較した図である。
Rxは、水素原子、炭素原子数1ないし8の低級アルキル基、F、Cl、Br及びIより選ばれたハロゲン原子、1ないし3個の炭素原子を有するアルコキシ基、ニトロ基、ヒドロキシ基、トリフルオロメチル基、及び1ないし3個の炭素原子を有するチオアルコキシ基からなる群より選択された一つを表し;
xは、1ないし3の整数を表し、ただし、xが2又は3のとき、Rは同じでも異なっていても良い;
R1及びR2は互いに同じでも異なっていてもよく、それぞれ独立して、水素原子、炭素原子数1ないし8の低級アルキル基、アリール基、アリールアルキル基、炭素原子数3ないし7のシクロアルキル基からなる群より選ばれ;
R1及びR2は、一緒になって、水素原子、アルキル基及びアリール基からなる群から選択された一つで置換された5ないし7員環の複素環を形成してもよく;
ここで、環状化合物は1ないし2の窒素原子及び0ないし1の酸素原子を含んでいてもよく;
ここで、前記窒素原子は互いに又は前記酸素原子と直接結合しない。)
で表される化合物又はその光学異性体、鏡像異性体、ラセミ体又はそれらの混合物、並びにその水和物、溶媒和物及び医薬品として許容できる塩類、エステル類、及びアミド類を特徴とする。
ここで、
式1aからなる群より選択されるD光学異性体が優勢であり、及び、
Rx,R1及びR2が好ましくは水素原子から選択され、
これは、O−カルバモイル−(D)−フェニルアラニノールであり、この化合物はまた、(R)−(ベータ−アミノ−ベンゼンプロピル)カルバメート 一塩酸と命名され得る下記式1bで表されるものであり; また、本明細書では「試験化合物」とも呼ぶ。
より合成的に製造し得る。
式1のひとつの化合物(ここで試験化合物と呼ぶ)は、(R)−(ベータ−アミノ−ベンゼンプロピル)カルバメート一塩酸塩であり、O−カルバモイル−(D)−フェニルアラニノールとも呼ばれる。
、紙面の平面へ突き出ている。)これは、絶対配置が(R)の右旋性(D)の光学異性体である。
試験段階後のアンケートの分析は、主に男性において、400mgの一日用量に於いて現れたピーク効果をもって、性への関心の増加及びオルガスムを持つ能力の効果を示す。この研究は、本化合物のこの特性を理解し評価する為に設計されたものではなかったが、それゆえ、試験化合物の具体的にこの特性の評価に関する更なる研究が行われるであろう。
その他の薬物の副作用
ここで用いた用語「抗うつ薬」とは、本発明のカルバメート化合物と併用して用いられ得る、哺乳類の抗うつ作用を有する事が知られている任意の化合物を意味するものとする。多くの最も一般的に用いられている抗うつ薬は、男性及び女性の両方に於いて性機能障害の重篤な、不都合な副作用を生じる。従って、この用語は、選択的セロトニン再取り込み阻害剤(SSRI‘s)、選択的セロトニン及びノルエピネフリン再取り込み阻害剤(SNRI’s);慣用の三環系抗うつ薬;ブプロピオン及びMAO阻害剤を含むが、これに限定されるものではない。
カルボキサミド)は、その実施例4としてミルナシプランを製造した、米国特許第4,478,836号公報に教示されている。この特許はこの化合物を抗うつ薬として記載している。Moret等、Neuropharmacology 24巻、1211−19頁(1985年)はそのセロトニン及びノルエピネフリン再取り込みの阻害剤としての薬理学的活性を記載している。
便宜上、明細書中、実施例及び添付の特許請求の範囲において用いたいくつかの用語をここに集める。
グルコン酸塩、グルタミン酸塩、グリコルイルアルサニレート、ヘキシルレソルシネート、ヒドラバミン、臭化水素酸塩、塩化水素酸塩、ヒドロキシナフトエート、ヨウ化物、イソチオネート、乳酸塩、ラクトビオン酸塩、ラウリン酸塩、リンゴ酸塩、マレイン酸塩、マンデル酸塩、メシル酸塩、メチル臭化物、メチル硝酸塩、メチル硫酸塩、ムケート、ナプシル酸塩、硝酸塩、オレイン酸塩、オキサル酸塩、パマオート(pamaote)、パルミチン酸塩、パントテネート(panthothenate)、燐酸塩/二燐酸塩、ポリガラクトウロン酸塩、カリウム、サリチル酸塩、ナトリウム、ステアリン酸塩、スベセテート(subacetate)、コハク酸塩、タンニン酸塩、酒石酸塩、テオクレート(teoclate)、トシレート、トリエチオダイド(triethiodide)、吉草酸塩等が挙げられるが、これらに限定されるものではない。
(1)の化合物は、任意の剤形を構成し得る。例えば、経口投与に適した剤形は、ピル、ジェルキャップ、タブレット、カプレット、カプセル(それぞれ、迅速な放出、時間調整した放出及び持続した放出の配合物を含む)、顆粒、及び粉末等の様な固体の剤形が挙げられる。経口投与の適した剤形はまた、溶液、シロップ、エリキシル剤、乳剤、及び懸濁液等の様な液体剤形が挙げられる。さらに、非経口投与に有用な剤形は、滅菌水溶液、乳剤及び懸濁液が挙げられる。
本発明は、医薬品として式1のラセミ混合物、光学異性体混合物及び分離された光学異性体を提供する。カルバメート化合物は、被験者に於ける補助的抗うつ作用をもたらす医薬品として形成される。
AR Remington‘s Pharmaceutical Sciences、17版、Mark Publishing Company、Easton PA、1985年、のような標準的文献に見出し得、前記文献の開示は、ここに全て参照として全て
の目的の為に取り込まれている。好適な液体担体、特に注射液用のものとしては、例えば、水、生理食塩液、水性デキストロース溶液、及びグリセロール等が挙げられる。
含む、いかなる無刺激性の固定油も用い得る。さらに、オレイン酸などの脂肪酸が注射剤の製造に於いて同様に使用し得る。これらの溶液は無菌であり一般的に望ましくない物質を含まない。
が挙げられるがこれらに限定されない。
照)
医薬品製造管理及び品質管理基準(GMP)規定の全面遵守のもとで形成される。
本発明は、カルバメート化合物を用いて哺乳類に於いて補助的抗うつ薬剤作用をもたらす方法を提供する。性機能障害を軽減し又は予防するのに必要なカルバメート化合物の量は治療及び医薬品有効量として定義される。投与レジュメ及びこの用途のための有効量、即ち投与又は用量レジュメは、疾病のステージ、患者の身体状況、年齢等を含む種々の因子に依存するであろう。患者への用量レジュメの計算に於いて、投与方法もまた考慮される。
する為に用いられ得る。
ラット及びマウスに於いては、試験化合物は抗うつ効果及びより高用量での自発運動に於ける刺激様効果を持つ。試験化合物の作用機構は明らかでないが、この薬理学的プロフィルは、central catecholaminergic pathway(セントラルカテコールアミン作動性経路)の活性化を含み得る。抗うつ効果に加え、central catecholaminergic(セントラルカテコールアミン作動性)の活性の増加は、実験動物や患者の性的挙動を増加させる事もまた知られている。(Foreman,MM及びHall,JL,“Effect of D2−dopaminergic receptor stimulation on the lordotic
response of female rats.”(「雌ラットのLordotic(前湾)反応に於けるD2−ドーパミン作動性レセプター刺激」)Psychopharmacology、91巻、96頁−100頁(1987年)、及び(Foreman,MM、“Disorder of sexual response:Pioneering new pharmaceutical and therapoutic opportunities.”(「性反応障害:先駆的な新薬及び治療の機会」)Exp. Opin.Invest.Drugs、4:621−636(1995)。
動物:ロングエヴァンス(Long−Evans) 雌ズキンラット(100ないし125g)雄スプラグ−ドーリー(Sprague−Dawley)ラット(150ないし175g)を、チャールスリバーブリーディングラボラトリーズより入手した。
試薬:プロゲステロン(Cat.番号P−0130;Lot 128H0456)及びエストロン(Cat.番号P−9750;Lot 28H0372)をシグマケミカルカ
ンパニーより購入し、キネロラン(Cat.番号Q−110;Lot PRF−694A)及びブプロピオン(Cat.番号B−102;Lot BS−11−10)をリサーチバイオケミカルインコーポレティッドより購入した。試験化合物(Lot番号D5−91B)はSKバイオファーマシューティカルセンター、ニュージャージー州、フェアフィールドに於いて合成した。エストロン及びプロゲステロンはプロピレングリコール(フィシャーサイエンティフィック P355−1;Lot番号992032)に溶解した。試験化合物、キネロラン及びブプロピオンは滅菌生理食塩水(0.9% NaCl、アボットラボラトリーズ、Lot 番号25−270−DK)に溶解した。
100mg/ml、フォードドッジラボラトリーズ、lot番号440339)100mg/kg皮下注射、及びキシラジン(Rompun 20mg/ml、バイエルコーポレーション、lot番号26050E)7mg/kg皮下注射.で麻酔した。腹面上の正中切開(1cm)を生殖器から約0.5−1cmのところから始めた。第二の切開(1cm)は、筋膜を連結する白線を通して、腹筋まで行った。子宮体は恥骨の近辺に位置し、そして腹部切開部から引き出した。卵巣及び子宮角を腹壁から引き出した。それぞれの子宮角を二分割して除去した子宮体付近で結さつた。腹壁を2回の縫合で閉じ、また皮膚切開部分を傷用クリップか又は縫合により閉じた。ラットを、麻酔から覚めるまで保温した。OVX=卵巣切除した。
試験化合物は10、30及び100mg/kg皮下注射.の用量での雌ラットの前湾挙動の用量依存性の上昇を生じた(表1)(図1も参照)。
(1)30及び100mg/kgに於ける試験化合物は、媒体処理に比べて有意に大きな前湾反応を生じた。参考までに、これらの動物の何体かは、その後にキネロラン(25μ
g/kg 皮下注射.)又はブプロピオン(30mg/kg 皮下注射.)のどちらかで処理した。キネロラン及びブプロピオンのどちらも媒体処理のものと比べlodotic反応の有意な上昇を生じた。
試験化合物の一つの可能な臨床的適用はうつ病の治療である(Foreman MM:(“Disorders of Sexual Response: Pioneering new pharmaceutical and therapoutic oppotunities.”「性反応の障害:新規医薬品及び治療機会」)、Exp. Opin.Invest.Drugs 4巻、621頁−636頁、1995年参照)
このあり得る副作用の評価として役立つ。現在の研究では、実験化合物の処理は、マウンティング行動のための前湾反応の用量依存的な増加を生じさせた。これらの効果の度合いは、患者の性反応を増加させる事が知られているキネロラン及びブプロピオンと類似のものであった。(Foreman MM:“Disorders of sexual response:Pioneering new pharmaceutical and therapoutic opportunities.”(「性反応の障害:新規医薬品及び治療機会」)、Exp. Opin.Invest.Drugs 4巻621頁−636頁、1995年参照)
・試験化合物は、卵巣切除したエストロゲン処理ラットの30及び100mg/kg 皮下注射.での前湾反応に於いて、統計的有意差のある用量依存的な増加を生じた。
・試験化合物の効果(効能)の度合いは、患者の性反応を増加させると報告されているキネロラン及びブプロピオンで観測されたものと同様であった。
・これらの研究結果は、試験化合物は性反応を抑圧せず、試験化合物は性障害の治療に有用であるという予備的証拠を提供する。
ここに示す全ての引用された文献は、その全てを参照によって、及び同様の範囲の目的の為に、個々の文献又は特許又は特許出願が、全ての目的の為にその全てに於いて参照として取り込まれる事と、具体的に、及び個々に示されたのと同程度に、ここに取り込まれる。
Claims (23)
- 式1からなる群より選択されるひとつの光学異性体が90%以上の範囲で優勢である、請求項2に記載の性機能障害治療薬。
- 式1からなる群より選択されたひとつの光学異性体が98%以上の範囲で優勢である、請求項2に記載の性機能障害治療薬。
- 式1aからなる群より選択されたひとつの光学異性体が90%以上の範囲まで優勢である、請求項5に記載の性機能障害治療薬。
- 式1aからなる群より選択されたひとつの光学異性体が98%以上の範囲まで優勢である、請求項5に記載の性機能障害治療薬。
- 式1bで表される光学異性体が90%以上の範囲で優勢である、請求項8に記載の性機能障害治療薬。
- 式1bで表される光学異性体が98%以上の範囲で優勢である、請求項8に記載の性機能
障害治療薬。 - 光学異性体の治療有効量が0.01mg/kg/投与から300mg/kg/投与である、請求項8に記載の性機能障害治療薬。
- 式1からなる群より選択されたひとつの光学異性体が90%以上の範囲で優勢である、請求項12に記載の性機能障害治療薬。
- 式1からなる群より選択されるひとつの光学異性体が98%以上の範囲で優勢である、請求項12に記載の性機能障害治療薬。
- 式1からなる群より選択されたひとつの光学異性体が90%以上の範囲で優勢である、請求項15に記載の性機能障害治療薬。
- 式1からなる群より選択されたひとつの光学異性体が98%以上の範囲で優勢である、請求項15に記載の性機能障害治療薬。
- 式1bで表される光学異性体が90%以上の範囲で優勢である、請求項18に記載の性機能障害治療薬。
- 式1bで表される光学異性体が98%以上の範囲で優勢である、請求項18に記載の性機能障害治療薬。
- 前記その他の治療薬が、選択的セロトニン再取り込み阻害剤(SSRI's);選択的セロトニン及びノルエピネフリン再取り込み阻害剤(SNRI's);慣用の三環系抗うつ薬(TCAs);モノアミンオキシダーゼ阻害剤(MAO−阻害剤)、モノアミンオキシダーゼの可逆的阻害剤(RIMAs)、第三級アミン三環系及び第二級アミン三環系抗うつ薬、からなる群より選択される、請求項18に記載の性機能障害治療薬。
- 前記その他の治療薬が、フルオキセチン、デュロキセチン、ベンラファクシン、ミルナシプラン、シタロプラム、フルボキサミン、パロキセチン、セルトラリン、5−MCA−NAT、炭酸リチウム(LiCO3)、イソカルボキサジド、フェネルジン、トラニルシプロミン、セレジリン、モクロベミド、カッパ−オピオイドレセプターアンタゴニスト;選択的ニューロキニンアンタゴニスト、コルチコトロピン放出因子(CRF)アンタゴニスト、タキキニンアンタゴニスト、α−アドレノレセプターアンタゴニスト、アミトリプチリン、クロミプラミン、ドクセピン、イミプラミン、ベンラファクシン、トリミプラミン、アモキサピン、デシプラミン、マプロチリン、ノルトリプチリン及びプロトリプチリン、及びその医薬品として許容できる塩類からなる群より選択される、請求項18に記載の性機能障害治療薬。
- 光学異性体の治療有効量が0.01mg/kg/投与から300mg/kg/投与である、請求項18に記載の性機能障害治療薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69280905P | 2005-06-22 | 2005-06-22 | |
US60/692,809 | 2005-06-22 | ||
PCT/US2006/023068 WO2007001841A1 (en) | 2005-06-22 | 2006-06-13 | Treatment of sexual dysfunction |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008546778A JP2008546778A (ja) | 2008-12-25 |
JP5298334B2 true JP5298334B2 (ja) | 2013-09-25 |
Family
ID=37067408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008518221A Active JP5298334B2 (ja) | 2005-06-22 | 2006-06-13 | 性機能障害を治療する方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8552060B2 (ja) |
EP (1) | EP1893291B1 (ja) |
JP (1) | JP5298334B2 (ja) |
KR (1) | KR101335942B1 (ja) |
AR (1) | AR054790A1 (ja) |
AT (1) | ATE459393T1 (ja) |
CA (1) | CA2612672C (ja) |
DE (1) | DE602006012670D1 (ja) |
ES (1) | ES2344469T3 (ja) |
MY (1) | MY145066A (ja) |
TW (1) | TWI387452B (ja) |
WO (1) | WO2007001841A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1890684B1 (en) | 2005-06-08 | 2013-08-14 | SK Biopharmaceuticals Co., Ltd. | Treatment of sleep-wake disorders |
US8741950B2 (en) | 2009-06-22 | 2014-06-03 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
JP5836280B2 (ja) | 2009-11-06 | 2015-12-24 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 注意欠陥/多動性障害(adhd)の治療方法 |
CA2779442A1 (en) | 2009-11-06 | 2011-05-12 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
SG11201507121RA (en) | 2013-03-13 | 2015-10-29 | Aerial Biopharma Llc | Treatment of cataplexy |
DK3021838T3 (da) | 2013-07-18 | 2020-08-24 | Jazz Pharmaceuticals Ireland Ltd | Behandling af fedme |
US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
TWI698415B (zh) | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
JP6466792B2 (ja) * | 2015-07-03 | 2019-02-06 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 注意欠陥/多動性障害(adhd)の治療方法 |
US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
FI3509582T3 (fi) | 2016-09-06 | 2024-02-08 | Axsome Malta Ltd | (r)-2-amino-3-fenyylipropyylikarbamaatin solvaattimuoto |
SG11201903076QA (en) | 2016-10-06 | 2019-05-30 | Jazz Pharmaceuticals International Iii Ltd | Carbamoyl phenylalaninol compounds and uses therof |
CN111201014A (zh) | 2017-06-02 | 2020-05-26 | 爱尔兰贾兹制药有限公司 | 治疗过度嗜睡的方法和组合物 |
CN111094238B (zh) | 2017-07-31 | 2023-06-09 | 杰资制药爱尔兰有限公司 | 氨基甲酰基苯丙氨醇类似物及其用途 |
US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA943862B (en) * | 1993-06-10 | 1995-12-04 | Lilly Co Eli | Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz[cd] indole-6-carboxamides |
KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
KR0173862B1 (ko) * | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
US6228864B1 (en) * | 1997-10-28 | 2001-05-08 | Vivus, Inc. | Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
US20050203130A1 (en) | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
AU2005302589B2 (en) * | 2004-10-28 | 2010-09-16 | Sk Biopharmaceuticals Co., Ltd. | Adjunctive therapy for depression |
EP1890684B1 (en) | 2005-06-08 | 2013-08-14 | SK Biopharmaceuticals Co., Ltd. | Treatment of sleep-wake disorders |
-
2006
- 2006-06-13 KR KR1020087001754A patent/KR101335942B1/ko active IP Right Grant
- 2006-06-13 DE DE602006012670T patent/DE602006012670D1/de active Active
- 2006-06-13 US US11/922,128 patent/US8552060B2/en active Active
- 2006-06-13 CA CA2612672A patent/CA2612672C/en not_active Expired - Fee Related
- 2006-06-13 ES ES06773098T patent/ES2344469T3/es active Active
- 2006-06-13 WO PCT/US2006/023068 patent/WO2007001841A1/en active Application Filing
- 2006-06-13 JP JP2008518221A patent/JP5298334B2/ja active Active
- 2006-06-13 EP EP06773098A patent/EP1893291B1/en active Active
- 2006-06-13 AT AT06773098T patent/ATE459393T1/de not_active IP Right Cessation
- 2006-06-20 MY MYPI20062920A patent/MY145066A/en unknown
- 2006-06-21 AR ARP060102653A patent/AR054790A1/es unknown
- 2006-06-21 TW TW095122189A patent/TWI387452B/zh active
Also Published As
Publication number | Publication date |
---|---|
AR054790A1 (es) | 2007-07-18 |
US8552060B2 (en) | 2013-10-08 |
KR101335942B1 (ko) | 2013-12-04 |
WO2007001841A1 (en) | 2007-01-04 |
TWI387452B (zh) | 2013-03-01 |
DE602006012670D1 (de) | 2010-04-15 |
ES2344469T3 (es) | 2010-08-27 |
EP1893291B1 (en) | 2010-03-03 |
CA2612672A1 (en) | 2007-01-04 |
JP2008546778A (ja) | 2008-12-25 |
ATE459393T1 (de) | 2010-03-15 |
EP1893291A1 (en) | 2008-03-05 |
MY145066A (en) | 2011-12-15 |
US20090221553A1 (en) | 2009-09-03 |
KR20080028445A (ko) | 2008-03-31 |
TW200727893A (en) | 2007-08-01 |
CA2612672C (en) | 2014-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5298334B2 (ja) | 性機能障害を治療する方法 | |
US11713292B2 (en) | Treatment of cataplexy | |
US8729120B2 (en) | Adjunctive therapy for depression | |
US9688620B2 (en) | Methods for treating fibromyalgia syndrome | |
JP5881692B2 (ja) | 双極性障害を治療する方法 | |
WO2024102718A1 (en) | Compositions and methods for treating insomnia | |
WO2024052895A1 (en) | Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120314 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120608 |
|
A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20121017 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130131 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130501 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130528 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5298334 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |